|Bid||87.50 x 900|
|Ask||87.93 x 1200|
|Day's Range||86.85 - 90.40|
|52 Week Range||75.35 - 123.99|
|Beta (5Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 18, 2020 - Feb 23, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||124.21|
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
Exact Sciences' (EXAS) preliminary quarterly results blew expectations out of the water.Yesterday, the molecular diagnostics company released preliminary results for its fourth quarter that exceeded analysts’ estimates. Total revenue for the quarter is expected to land between $294 million and $296 million, reflecting a top-line beat of about $4 million to $6 million.The better-than-expected outcome was primarily driven by its acquisition of Genomic Health, which was finalized back in November and gave it access to Oncotype DX gene expression tests that have been used in treatment decisions for over 1 million cancer patients globally. During the quarter, Oncotype DX test volume growth of 14%, or total test volume of 41,000, helped Genomic Health generate revenue of between $118 and $119 million, up 13% year-over-year.On top of this, Cologuard, its FDA approved noninvasive, at-home colon cancer screening test, will most likely see revenue come in within the range of $229 million to $230 million. While this falls in line with the consensus estimate, BTIG analyst Amanda Murphy reminds investors that the difference between consensus and guidance is the highest it has been this year. She points out that “consensus for Cologuard revenue was at the high-end of management’s guidance range for the quarter.” If achieved, the figure would also represent a year-over-year increase of 61%.Based on the expected Cologuard revenue, it isn’t surprising to the analyst, then, that volumes for the screening test are also expected to match the estimate. The results indicate Cologuard test volume of 477,000 could be in store. This, however, would not only come in above management’s guidance of between 465,000 to 475,000, but also reflect impressive growth of 63%.While management isn’t offering any 2020 guidance before its earnings call in February, Murphy notes that the results reaffirm her already established bullish thesis. “Since Cologuard was approved in 2014, Exact has secured broad reimbursement coverage, developed a large and experienced sales force, increased its lab capacity to seven million tests per year, and made significant investments in IT infrastructure. We believe Cologuard is currently at an inflection point and expect the company to hit its long-term goal of 40% market penetration by the end of 2030,” she explained. The four-star analyst added, “While not explicitly included in our current valuation model, we are also optimistic around the potential for Exact's liquid biopsy test for liver cancer.”Bearing this in mind, Murphy maintained both a Buy rating as well as a $127 price target. This conveys her confidence in Exact’s ability to climb 40% higher in the next twelve months. (To watch Murphy’s track record, click here)As for the rest of the Street? It turns out that other analysts wholeheartedly agree with the BTIG analyst. Out of 9 total analysts that have published a recommendation over the last three months, 100% see the stock as a Buy. This makes the consensus rating a unanimous Strong Buy. Not to mention the $123.56 average price target puts the upside potential just below Murphy’s forecast at 37%. (See Exact Sciences stock analysis on TipRanks)
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
With the $2.8 billion acquisition deal of California's Genomic Health officially completed, Madison-based Exact Sciences Corp. is calculating the estimated combined revenues earned by both companies for the recent fourth quarter.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $294 million and $296 million for the fourth quarter ended Dec. 31, 2019.
Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following investor conference and invited investors to participate by webcast.
(Bloomberg) -- If in the throes of this bull market’s earliest stages of recovery someone told you to forgo stocks, forget commodities, renounce fixed-income assets and buy an unknown digital token, the first of its kind, and watch it grow beyond your wildest dreams, you’d call them crazy, right?Emerging out of the ashes of the financial crisis, Bitcoin was created as a bypass to the banks and government agencies mired in Wall Street’s greatest calamity in decades. At first, it was slow to break through, muddied by a slew of scandals: fraud, thefts and scams that turned away many and brought closer regulatory scrutiny. But once it burst into the mainstream, it proved to be the decade’s best-performing asset.The largest digital token, trading around $7,200, has posted gains of more than 9,000,000% since July 2010, according to data compiled by Bloomberg.“Bitcoin really captured that wild technology enthusiasm that ‘this time is different,’” said Peter Atwater, the president of Financial Insyghts and an adjunct professor at William & Mary in Williamsburg, Virginia.The performance over the past 10 years, even with its huge run-up and subsequent mega-crash, leaves all others in the dust. It’s a massive windfall for those who HODL’ed through its ups and downs, even as it continues to provide fodder for get-rich-quick schemes. For some, the never-ending fantasy of continually hitting that payoff still helps to keep Bitcoin’s momentum going.Nothing else comes even close to beating it. The S&P 500 merely tripled in that period. An index that tracks world markets has more than doubled. Gold is up 25%. Some of the best-performing stocks in the Russell 3000 -- including Exact Sciences Corp. and Intelligent Systems Corp. -- are each up about 3,000%. Those gains pale in comparison to the finance world’s latest -- and one of its most controversial -- marvels.Partly, the monster return is a reflection of the calculus behind Bitcoin’s jumping-off point: the token wasn’t worth anything when someone named Satoshi Nakamoto launched it on Halloween 2008. Designed as a method of exchange that can be sent electronically between users around the world, it did not have a centralized control network. Bitcoin, instead, is run by a network of computers that keep track of all transactions on the blockchain ledger. For many, that technology was reason enough to buy into the idea.On the other side of the equation are Bitcoin’s devoted enthusiasts who saw in its technology a promising way to change the global financial system.“This is the first time that there’s a real separation -- just like church and state -- you have a separation of money and state,” said Alex Mashinsky, founder of Celsius Network, a crypto lending platform. “That’s the innovation, that’s the excitement.”But Bitcoin was slow to take off, notching its first transaction two years after its creation, when someone used it to buy pizza. Since then, the first-born token’s price has catapulted, doubling many times over, and hundreds of imitators have cropped up -- some with more success than others.Many of those who got in early stayed faithful, watching as it made its way through a boom and bust cycle unrivaled by almost anything else over the last decade.At the beginning of 2017, Bitcoin jumped above $1,000. By mid-summer, it had more than doubled. Insanity was unleashed. By year-end, it hovered above $14,000. But as swiftly as it ran up, it fell even faster. By the end of 2018, Bitcoin barely budged above $3,000. Yet shortly after its crash, it embarked on another huge rally, this time reaching as high as $13,800 in the summer of 2019.“Certainly the numbers are what appeals to investors,” said David Tawil, president of ProChain Capital. “The next 10 years need to be a totally different stage of growth based on totally different factors than the first stage.”As much as it’s made a fortune for speculators and some thieves, Bitcoin’s survival will rest on further adoption. It’s not being used as a widespread medium of exchange. A few large retailers are accepting payment in Bitcoin but it hasn’t been the large-scale embrace so many had predicted. Scams are still running rampant. Interest is waning and consolidation among large owners is at a higher level than it was during the height of the 2017 bubble, which means that their influence over prices could be increasing.Projections for the next decade abound. In the 2020s, mass adoption is surely to take off, they say. Blockchain technology will revolutionize and solve every problem in the world. On the other hand, regulatory scrutiny is likely to intensify, with central bankers paying closer attention than ever before.In the more immediate term, some speculators forecast 2020 might be less fraught with volatility given its upcoming halving, whereby the number of coins awarded to so-called miners who process transactions is cut by 50%. That’s set to happen in May 2020 (the internet is replete with countdown clocks). The coin’s previous cut, about four years ago, coincided with a run-up in its price, pushing many crypto evangelist to believe in a repeat.To CoinList’s Andy Bromberg, the halving is already priced in. “Maybe it’s been overpriced in and everyone’s bought into this thesis and we see a dip post-halving,” said the firm’s co-founder and president in an interview. “That would not shock me.”But beyond next year, “Bitcoin is finding its own narrative as digital gold,” he said. “It feels like that narrative is picking up steam and it’s breaking away on its own. I would define success for most crypto assets as doing exactly that.”To contact the reporter on this story: Vildana Hajric in New York at email@example.comTo contact the editors responsible for this story: Jeremy Herron at firstname.lastname@example.org, Dave Liedtka, Randall JensenFor more articles like this, please visit us at bloomberg.com©2020 Bloomberg L.P.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
One area of the market that has been gaining steam: biotech stocks. A flurry of deals, FDA approvals, and recent innovations in the biotech space have seen the Nasdaq Biotechnology Index exhibit a quarterly uptick of 24%, easily beating the S&P 500’s 8.3% quarterly gain. The recent surge has helped the sector close the gap on the S&P 500’s stellar 2019, and a 27% year-to-date increase brings it into the realm of the major index’s 29% yearly gain.While earlier in the year, the sector as a whole may have lagged behind the general market trend, the biotech industry’s infamous volatility still managed to produce some outstanding performers in 2019. According to the analysts, some are set for further growth in 2020.Based on the information provided by the Stock Screener tool from TipRanks, a company that tracks and measures the performance of analysts, three companies appear ready to take advantage of the sector’s upturn. As it happens, all three currently have a Strong Buy consensus rating from the Street, too.Alexion Pharmaceuticals (ALXN)Interestingly enough, one biotech yet to match the sector’s performance this year is Alexion Pharmaceuticals. Although its share price is up by 13% year-to-date, the figure is significantly below the biotech industry’s yearly gain. Some on the Street, though, think that is about to change.ALXN is a leading developer of drugs for rare and ultra-rare indications, especially in neuromuscular diseases. The company’s most successful drug is Soliris, a treatment for a number of conditions including rare blood disease, hemolytic uremic syndrome (HUS). Other products include Ultomiris, a treatment for adults with PNH (Paroxysmal Nocturnal Hemoglobinuria), and Strensiq, a treatment for infantile and juvenile onset hypophosphatasia (HPP).Alexion recently entered into an option agreement with Stealth Biotherapeutics for elamipretide, a therapy for primary mitochondrial myopathy (PMM). In return for a $30 million investment, the companies will co-develop and co-promote elamipretide in the U.S., and Alexion will receive the exclusive rights to the drug for the rest of the world. It is thought that around 40,000 people in the U.S. are affected by the disease, which is characterized by debilitating skeletal muscle weakness.Nomura’s Christopher Marai thinks elamipretide could see global sales of over $2 billion. The 4-star analyst noted, “We anticipate the Ph3 data imminently (in late Dec/early Jan); this offers a near-term catalyst on what could be ALXN’s next blockbuster drug opportunity. We expect the next few earnings quarters for ALXN to be positive, with continued MG, NMOSD, and Ultomiris conversion-based rev. growth providing a solid valuation foundation and few near-term negative-catalyst risks.”Marai has no issue, then, in maintaining his Buy thesis on Alexion. The accompanying target price of $165 conveys Marai’s belief that the share price could increase by 50% over the next year. (To watch Marai’s track record, click here)Alexion has healthy support from the rest of the Street, too. A breakdown of the company’s Strong Buy consensus rating exhibits 12 Buys and 3 Holds. The average price target of $145.67, indicates there is room for an additional 32% increase over the next 12 months. (See Alexion stock analysis on TipRanks) Exact Sciences Corporation (EXAS)Completely ignoring the notion that biotechs have lagged behind the market is Exact Sciences. The cancer prevention focused company is up 53% year-to-date.The company’s flagship product is the colon cancer test, Cologuard. According to CEO Kevin Conroy, the next few years should see the drug’s current 5% market penetration increase to 40%. The US alone has a population of 105 million who are eligible to use the test, indicating a market in the range of $20 billion for the company to get a piece of.In recent news, November saw the company close the $2.8 billion acquisition of genomic diagnostics maker Genomic Health. The deal expands Exact Sciences’ presence to more than 90 countries.According to Cowen’s Doug Schenkel, EXAS is severely undervalued. The 5-star analyst thinks, “EXAS is positioned to generate organic revenue growth of ~25-50% annually over at least the next 5-years while generating solid [free cash flow].”Schenkel further added, "EXAS remains our favorite large-cap, growth stock pick. We see a path to ~50% upside from current levels over the NTM. We expect robust Cologuard growth that exceeds Street expectations, are increasingly positive on how much GHDX can help EXAS commercially and operationally, believe the product pipeline is under-appreciated, and feel concerns are disproportionally captured in current valuation."No surprise, then, to learn Schenkel maintained an Outperform rating on EXAS, while reducing the price target by $5 to $130. With EXAS stock currently trading at $96.50, this implies upside of 35%. (To watch Schenkel’s track record, click here)Does the rest of the Street concur? Yes, it does, in no uncertain terms. A unanimous 10 Buys form a Strong Buy consensus rating. The average price target of $123.70 indicates a possible 28% increase in the coming year. (See Exact Sciences stock analysis on TipRanks) See also: 3 Market-Beating Stocks to Snap Up for 2020Zealand Pharma A/S (ZEAL)Another company totally outperforming the market in 2019 is the metabolic and gastrointestinal disease specialist, Zealand Pharma. The Denmark based biotech’s main area of focus is on the discovery, design, and development of peptide-based medicines. Zeal has got a lot of investors excited, as its share price has risen an outstanding 183% year-to-date.So, what’s the fuss all about? The company’s recent 3Q report gives an indication of the volume of activity at Zeal. Among the highlights were the positive results of the Phase 3 clinical programs for dasiglucagon, the company’s treatment for hypoglycemia. The focus now turns to preparation of the NDA for submission in early 2020.Zealand also completed its first ever acquisition of Encycle Therapeutics, in a deal that could potentially cost $80 million. The Toronto based biotech provides technology to synthesize macrocyclic peptides with drug-like properties. Furthermore, Zealand secured private funding from Van Herk Investments, in the shape of about $83 million. The additional funding will go towards supporting Zealand Pharma’s peptide platform and to speed up current development of late stage assets.All the positive developments haven’t gone unnoticed by Goldman Sachs’ Graig Suvannavejh, who noted the company's increasingly positive pipeline and commercial execution. The 4-star analyst thinks Zealand Pharma "finds itself on the cusp of transforming" into a commercial stage company in the foreseeable future.To this end, Suvannavejh upgraded his rating from Neutral to Buy and set a price target of $41, implying the Danish biotech has room for growth in the shape of another 25%. (To watch Suvannavejh’s track record, click here)2 other analysts have chimed in with a view on Zealand in the last three months, both also giving the biotech a thumbs up. The Strong Buy consensus rating is accompanied by an average price target of $39.33, implying upside potential of 20%. (See Zealand Pharma price targets and analyst ratings on TipRanks) Check out these 5 ‘Strong Buy’ stocks that top Wall Street analysts recommend.
Cowen analyst Doug Schenkel says Exact Sciences is his top pick among large-capitalization growth stocks.
Exact Sciences Corp. (NASDAQ: EXAS) today announced new outcomes data from two large population-based studies1,2 presented at the 2019 San Antonio Breast Cancer Symposium (SABCS®). The real-world evidence suggests that use of the Oncotype DX Breast Recurrence Score® test in clinical practice is consistent with previous clinical validation studies including TAILORx, the largest ever breast cancer treatment trial. This landmark study was featured in the William L. McGuire Memorial Lecture Award, which recognized Joseph A. Sparano, M.D., TAILORx study chair, for his leadership, collaboration and practice-changing achievements in breast cancer research.